Reconsidering Adjuvant Immunotherapy for Tuberculosis
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Shortened regimens for treatment of pulmonary tuberculosis (TB) are urgently needed to facilitate its global eradication. Prolonged treatment is presently required to prevent relapse, which is thought to arise from persisting foci of semidormant infection contained within granulomas. METHODS: The medical literature was reviewed to identify clinical trials of adjuvant TB immunotherapy, as well as other studies of the relationship between immune status and TB relapse or reactivation. RESULTS: Four studies of therapeutic interferon indicated its inability to effectively augment the mycobactericidal capacity of lung macrophages. One randomized, placebo-controlled trial of therapeutic interleukin-2 found that it delayed the microbiologic response to treatment, whereas 2 controlled trials of anti-tumor necrosis factor (TNF) therapies (high-dose prednisolone and etanercept [a soluble TNF receptor]) found that these interventions significantly accelerated the response to treatment. Four retrospective studies were identified in which the response to TB therapy was accelerated and/or the relapse risk was reduced in persons with human immunodeficiency virus coinfection; one study reported that immune reconstitution syndrome due to use of antiretroviral therapy was associated with increased risk of relapse. Several studies indicated that granulomas may be efficiently targeted and disrupted by the anti-TNF antibody infliximab, apparently because of its ability to bind to cell-surface TNF and to induce apoptosis in TNF-expressing cells. CONCLUSIONS: These findings support the hypothesis that the granulomatous host response to TB may paradoxically protect sequestered mycobacteria from administered anti-TB therapy and that treatment may be improved by therapeutic disruption of granulomas. Clinical trials to test this hypothesis are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149 · cited 1×
“ing domains, as a soluble homotrimer [26, 27].”
Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schrelber, R., Mak, T. W., & Bloom, B. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90001-2 · Cited by 1,677 · cited 1×
“As a result, animals deficient in TNF are highly susceptible to granulomatous infections [41].”
BackgroundMcKinney, J. D., zu Bentrup, K. H., Muñoz-Elías, E. J., Miczak, A., Chen, B., Chan, W.-T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., & Russell, D. G. (2000) · Nature · doi:10.1038/35021074 · Cited by 1,360 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundKindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254 · cited 1×
“tuberculosis infection and inhibits the orderly formation of granulomas [37, 38].”
BackgroundChan, J., Xing, Y., Magliozzo, R. S., & Bloom, B. R. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.4.1111 · Cited by 1,062 · cited 1×
“production of reactive nitrogen intermediates, such as nitric oxide [16, 17].”
BackgroundGranulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Self-citationInhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program
Voskuil, M. I., Schnappinger, D., Visconti, K. C., Harrell, M. I., Dolganov, G. M., Sherman, D. R., & Schoolnik, G. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030205 · Cited by 966 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundEtanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910 · cited 1×
“Crohn disease, sarcoidosis, or Wegener granulomatosis [68-71].”
Interferon-γ –Receptor Deficiency in an Infant with Fatal Bacille Calmette–Guérin Infection
Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J.-F., Newport, M., Levin, M., Blanche, S., Seboun, E., Fischer, A., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352604 · Cited by 895
Research works printed but not linked: 10
- O’Brien RJ, 2001, Global Alliance for TB Drug Development. Tuberculosis, 81, 1
- Giosue S, 2000, Eur Cytokine Netw, 11, 99
- InterMune investor relations press release: InterMune enrolls first patient in phase III trial in multidrug-resistant tuberculosis. 2000. Available at: http://www.hopkins-tb.org/news/7-31-2000.shtml. Accessed 18 May 2005.
- de Oliveira MM, 2004, Jornal Brasileiro Pneumologia, 30, 461
- East African-British Medical Research Councils, 1974, Lancet, 2, 237
- Bilaceroglu S, 1999, Int J Tuberc Lung Dis, 3, 47
- Dhillon J, 1989, Br J Exp Pathol, 70, 103
- Batten JC, 1957, Br J Exp Pathol, 38, 424
- Flynn JL, 2004, Tuberculosis. Philadelphia: Lippincott Williams & Wilkins, 237
- Joloba ML, 2000, Int J Tuberc Lung Dis, 4, 528
Cited by
Roca, F. J., & Ramakrishnan, L. (2013) · Cell · doi:10.1016/j.cell.2013.03.022 · Cited by 592
“Second, that these susceptibility pathways could be TNF-mediated is supported by a clinical trial from Uganda showing that pulmonary TB patients had increased clearance of sputum bacteria when treated with TNF blocking agents (Wallis, 2005).”
ResultHost Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections
Tobin, D. M., Roca, F. J., Oh, S. F., McFarland, R., Vickery, T. W., Ray, J. P., Ko, D. C., Zou, Y., Bang, N. D., Chau, T. T. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.023 · Cited by 580
“In addition, anti-TNF therapies have been reported to accelerate the bacteriological response in pulmonary TB patients (Wallis, 2005).”
BackgroundCurrent diagnosis and management of peripheral tuberculous lymphadenitis.
Fontanilla, J.-M., Barnes, A., & von Reyn, C. F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir454 · Cited by 299
“Adjuvant immunotherapy with anti–tumor necrosis factor agents has been studied in small numbers of patients for routine treatment of all forms of tuberculosis, but available data are insufficient to make a recommendation [51].”
BackgroundTumour necrosis factor antagonists: structure, function, and tuberculosis risks
Wallis, R. S. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70227-5 · Cited by 275
Self-citationThe risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement
Bumbacea, D., Arend, S. M., Eyuboglu, F., Fishman, J. A., Goletti, D., Ison, M. G., Jones, C. E., Kampmann, B., Kotton, C. N., Lange, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00000712 · Cited by 264
“Potential improvement could be obtained by new drug combinations including novel drugs such as the diarylquinoline TMC207 [167], or combinations with immunopotentiators [168, 169].”
Background
Metadata
- Authors
- Wallis, R. S.
- Affiliations
- Pharmaceutical Product Development (United States) (US)
- Corresponding author
- Wallis, Robert S.
- ORCID
- Wallis, Robert S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-15
- Volume
- 41
- Issue
- 2
- Pages
- 201-208
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2133199321
- Cited by
- 121
- References
- 75
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 7 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 13
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Louisiana State University
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- pulmonary tuberculosis, adjuvant immunotherapy, tuberculosis relapse, granuloma, anti-TNF therapy, infliximab, etanercept, prednisolone, interleukin-2, interferon therapy, HIV coinfection, immune reconstitution inflammatory syndrome, antiretroviral therapy, tuberculosis treatment response
- MeSH terms
- Antitubercular Agents, Humans, Immunotherapy, Tuberculosis, Pulmonary, Drug Resistance, Multiple, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reconsidering Adjuvant Immunotherapy for Tuberculosis. https://app.cochat.ai/papers/10.1086/430914
- The paper
- Wallis, R. S. (2005). Reconsidering Adjuvant Immunotherapy for Tuberculosis. Clinical Infectious Diseases. https://doi.org/10.1086/430914
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.